Free Articles at Neutron Marketing Article Publishing and Distribution » Cancer » Are we "Livin" or just "Survivin"?
Previous Article - Transcriptional Factors And Regulators
Next Article - New FOXP3Δ2 (Exon 2 Deleted) Specific Antibody

View PDF | Print View | Html Version
by: Stephen Jones
Total views: 21
Word Count: 201

The inhibitor of apoptosis (IAP) family protects cells from self-execution by blocking the relentless caspase death cascade. IAPs bind to and inhibit activated caspases through their BIR domains.  Some IAPs such as    Livin also contain a RING domain that has E3 ubiquitin ligase activity and promotes the degradation of    Smac/DIABLO through ubiquitination. Since Smac/DIABLO promotes apoptosis by inhibiting IAP-caspase interactions, degradation of Smac/DIABLO allows IAPs to more effectively block caspase activity thereby promoting cell survival.

 

In general, members of the IAP family are highly expressed in several types of cancer. However, Survivin, an IAP that lacks a RING domain, definitely stands out among the family for its clear association with cancer. Abundantly expressed during development but scarce in normal adult tissues, Survivin is upregulated during tumorigenesis and associated with chemotherapy resistance and poor patient survival.

 

IAPs are fast emerging as targets for potential diagnostics and therapeutics. For example, patients suffering from diverse cancers develop antibodies against Livin suggesting that Livin may be a novel diagnostic or prognostic tumor marker. Additionally, preclinical studies indicate that down-regulation of Survivin can sensitize tumor cells to chemotherapy, thereby increasing apoptosis and overall treatment response.

About the Author

IMGENEX India Pvt Ltd. the only biotech company in Orissa and one of its kinds in

Eastern India. IMGENEX India started in Oct as an outsourcing branch of  IMGENEX Corporation , San Diego, USA.  Find out more  information about  Apoptosis.

 

---

Rating: Not yet rated

--Choose-- 0 1 2 3 4 5

No comments posted.

Add Comment

Enter the code shown